INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The provider file / Dossier 371
RESEARCH DOSSIER / NOT AN ENDORSEMENT

Apex Pharma

A dated business research record, with the original field-level evidence labels kept intact.

Source snapshot: 2026-10-29. “Verified” below is the source dataset author’s label—not an independent license, safety, quality or clinical audit by Modern Dosing. These pages are excluded from search indexing until reviewed.
Positioning & service claimsread

UK research supplier: retatrutide vials and 'Reta Pen' (Newcastle, UK)

Audienceread

Research-compound buyers; audience not assessed in this pass.

Pricing & termsnot_found

Product prices not captured in this pass.

    Clinical relationshipspartial

    No clinical care; direct-to-consumer research-compound storefront. Products labeled research use only (RUO), not for human consumption.

    Pharmacy & fulfillmentpartial

    None; sells research compounds directly, no pharmacy layer.

    Advertising snapshotnot_found

    Ad libraries not checked in this pass.

      Founding yearnot_found

      Not established in this pass.

        Foundersnot_found

        Not established in this pass.

          Location & entity contextread

          Newcastle, UK

            Search visibility samplenot_found

            Not assessed in this pass.

              THE MODERN DOSING WEEKLY

              The peptide news
              that changes your week.

              Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.